Liraglutide Injection — once-daily human GLP-1 analogue for type 2 diabetes and chronic weight management, with proven cardiovascular risk r
Liraglutide Injection — once-daily human GLP-1 analogue for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. GMP manufactured with full documentation (COA, COPP, DMF, CTD Dossiers) and validated cold-chain export.
| Product Name | Liraglutide Injection (GLP-1 Receptor Agonist) |
|---|---|
| Dosage Form | Injection |
| Strength | 6 mg/mL — 3 mL prefilled pen (18 mg/3 mL) |
| Standards | BP / ENTERPRISE |
| Packing | Prefilled pen, 1 or 3 pens/box; cold-chain 2–8°C shipping |
| Documents | COA, COPP, DMF, CTD Dossiers |
| MOQ | Contact us for MOQ and current stock |
Reference information summarised from WHO prescribing guidance. Expand each item below — clinical use must always follow the locally approved product insert.
Reference: WHO Model Formulary / WHO Model List of Essential Medicines. For professional reference only — clinical use must follow the locally approved product insert and national treatment guidelines.
Full batch testing and quality traceability under standard GMP workshops.
Sufficient stock on regular items, familiar with export logistics to 50+ countries.
COA, DMF, dossier and legalization documents for your market registration.